ReviewBioImpacts : BI2018
An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development.
Review in BioImpacts : BI, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Artificial neural network guided optimization of tenofovir and Cyanovirin-N multipurpose preventive hydrogel formulation developed using the Box Behnken design model.Pharmaceutical science advances · 2025Article
- Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes.Viruses · 2025Article
- The Antiviral Potential of Algal Lectins.Marine drugs · 2023Review
- The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro.Scientific reports · 2023Article
- Cyanometabolites: molecules with immense antiviral potential.Archives of microbiology · 2023Review
- Therapeutic Potential of Marine Bioactive Peptides against Human Immunodeficiency Virus: Recent Evidence, Challenges, and Future Trends.Marine drugs · 2022Review
- Article
- Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases.Plant biotechnology journal · 2021Review
- Cyanobacteria-From the Oceans to the Potential Biotechnological and Biomedical Applications.Marine drugs · 2021Review
- Antiviral Cyanometabolites-A Review.Biomolecules · 2021Review
- Antiviral Potential of Algal Metabolites-A Comprehensive Review.Marine drugs · 2021Review
- The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.Molecules (Basel, Switzerland) · 2020Review
- Bioactive Peptides Produced by Cyanobacteria of the GenusMarine drugs · 2019Review
- Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity.MedChemComm · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.